|
Ipriflavone is made in the laboratory from another substance (daidzein) that is taken from soy. Soy is a plant.
Ipriflavone is used for preventing and treating weak bones (osteoporosis) in older women, preventing osteoporosis caused by certain medications, relieving pain associated with osteoporosis, and treating a bone disease called Paget's disease. It is also used for reducing bone loss caused by chronic kidney disease (renal osteodystrophy) and by paralysis associated with stroke. Researchers have found that paralyzed stroke patients have weaker bones on the affected side, possibly due to immobility as well as vitamin D deficiency. Vitamin D deficiency may stem from lack of exposure to sunlight.
Ipriflavone is also used by bodybuilders to increase metabolism. Ipriflavone may prevent bone strength loss, and help improve the effects of estrogen in preventing osteoporosis. When used in combination with estrogens, it might allow lower estrogen doses to be used in postmenopausal women.
What is Ipriflavone?
Ipriflavone is a synthetic isoflavone which may be used to inhibit bone resorption, maintain bone density and to prevent osteoporosis in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.
How it is made
Ipriflavone is a substance man-made in the laboratory from another substance (daidzein) that is derived from soy.
Where it is found
Ipriflavone does occur naturally in food but only in trace amounts. It is available as a nutritional supplement.
Benefits / uses
|
|
Possible Side effects / Precautions / Possible Interactions:
Ipriflavone is LIKELY SAFE for most people when used with proper medical supervision. It can cause side effects such as stomach pain, diarrhea, or dizziness.
There is some concern that ipriflavone can cause a decreased white cell count (lymphocytopenia) in people taking it for greater than six months. White cell counts should be monitored, especially in people taking ipriflavone long-term.
Special Precautions & Warnings:
Pregnancy and breast-feeding: Not enough is known about the use of ipriflavone during pregnancy and breast-feeding. Stay on the safe side and avoid use.
Weak immune system: Ipriflavone can lower the body’s white cell count, making it more difficult for the body to fight off infection. This is be especially concerning in people who already have a weak immune system due to AIDS, drugs used to prevent organ rejection after transplant, chemotherapy, or other causes. If you have a weak immune system, check with your healthcare provider before starting ipriflavone.
Low white cell count (lymphocytopenia): Since ipriflavone can cause lymphocytopenia, there is a concern that it might make pre-existing lymphocytopenia worse.
Interaction:
Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with IPRIFLAVONE
Some medications are changed and broken down by the liver.
Ipriflavone might decrease how quickly the liver breaks down some medications. Taking ipriflavone along with some medications that are changed by the liver might increase the effects and side effects of some medications. Before taking ipriflavone talk to your healthcare provider if you take any medications that are changed by the liver.
Some of these medications that are changed by the liver include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline, zileuton (Zyflo), zolmitriptan (Zomig), and others.
Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with IPRIFLAVONE
Some medications are changed and broken down by the liver.
Ipriflavone might decrease how quickly the liver breaks down some medications. Taking ipriflavone along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking ipriflavone talk to your healthcare provider if you take any medications that are changed by the liver.
Some medications that are changed by the liver include amitriptyline (Elavil), diazepam (Valium), zileuton (Zyflo), celecoxib (Celebrex), diclofenac (Voltaren), fluvastatin (Lescol), glipizide (Glucotrol), ibuprofen (Advil, Motrin), irbesartan (Avapro), losartan (Cozaar), phenytoin (Dilantin), piroxicam (Feldene), tamoxifen (Nolvadex), tolbutamide (Tolinase), torsemide (Demadex), warfarin (Coumadin), and others.
Medications that decrease the immune system (Immunosuppressants) interacts with IPRIFLAVONE
Ipriflavone might decrease the immune system. Taking ipriflavone along with other medications that decrease the immune system might decrease the immune system too much. Avoid taking ipriflavone with medications that decrease the immune system.
Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others.
Theophylline interacts with IPRIFLAVONE
The body breaks down theophylline to get rid of it. Ipriflavone might decrease how quickly the body gets rid of theophylline. Taking ipriflavone along with theophylline might increase the effects and side effects of theophylline.
Reference& Research |
 |
Murray M & Pizzorno ND: Encyclopedia of Natural Medicine (2nd ed). Prima Press, Rocklin, CA; 1998. |
|
Brandi ML: new treatment strategies: Ipriflavone, Strontium, Vitamin D Metabolites and Analogs. Am J Med 1993; 95(Suppl.5A): 69S-74S. |
|
Moscarini M,Patacchiola F, Spacca G et al: New Perspective in the treatment of Postmenopausal Osteoporosis - Ipriflavone. Gynecol Endocrinol 1994; 8:203-207. |
|
Passeri M, Biondi M, Costi D et al: Effect of ipriflavone on bone mass in elderly osteoporotic women. Bone Miner 1992;19(supp1):S57-S62. |
|
Agnusdei D, Crepaldi G, Isaia et al: A double blind placebo-controlled trial of Ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997;61:142-147. |
|
Agnusdei D, Zacchei F, Bigazzi S et al: Metabolic and clinical effects of ipriflavone in established postmenopausal osteoporosis. Drugs Exp Clin Res 1989; 15(2):97-104. |
|
Takahashi J, Kawakatsu K, Wakayama T et al: Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease. Eur J Clin Pharmacol 1992; 43:207-208. |
|
Shino M: Pharmacokinetic study of ipriflavone by oral administration in healthy male volunteers. Jpn Pharmacol Ther 1985; 13:235. |
|
Ju YH, Doerge DR, Allred KF et al: Dietary genestein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002; 62(9):2474-2477. | |